MINDMAZE THERAPEUTICS HOLDING SA Total Assets
MINDMAZE THERAPEUTICS HOLDING SA total assets. Based on the latest financial reports, MINDMAZE THERAPEUTICS HOLDING SA (MMTX) holds total assets worth CHF44.11 Million CHF (≈ $55.76 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of MINDMAZE THERAPEUTICS HOLDING SA for the company's overall valuation and market capitalisation.
Total Assets of MINDMAZE THERAPEUTICS HOLDING SA (2024–2025)
Total assets of MINDMAZE THERAPEUTICS HOLDING SA from 2024 to 2025. This chart illustrates how MINDMAZE THERAPEUTICS HOLDING SA's total assets have evolved over time, based on quarterly financial data. See MMTX share price today for real-time trading data and today's change.
MINDMAZE THERAPEUTICS HOLDING SA - Asset Composition Analysis
MINDMAZE THERAPEUTICS HOLDING SA Total Assets Breakdown (December 2025)
MINDMAZE THERAPEUTICS HOLDING SA total assets breakdown as of December 2025. MINDMAZE THERAPEUTICS HOLDING SA's total assets of CHF44.11 Million consist of 25.5% current assets and 74.5% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 18.4% |
| Accounts Receivable | CHF1.02 Million | 2.0% |
| Inventory | CHF1.14 Million | 2.2% |
| Property, Plant & Equipment | CHF0.00 | 0.0% |
| Intangible Assets | CHF7.89 Million | 15.3% |
| Goodwill | CHF28.40 Million | 55.1% |
Asset Composition Trend (2024–2025)
This chart illustrates how MINDMAZE THERAPEUTICS HOLDING SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of MINDMAZE THERAPEUTICS HOLDING SA to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MINDMAZE THERAPEUTICS HOLDING SA's current assets represent 25.5% of total assets in 2025, an increase from 0.0% in 2024.
- Cash Position: Cash and equivalents constituted 18.4% of total assets in 2025, up from 0.0% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 70.0% of total assets, an increase from 0.0% in 2024.
- Asset Diversification: The largest asset category is goodwill at 55.1% of total assets.
MINDMAZE THERAPEUTICS HOLDING SA Competitors by Total Assets
Key competitors of MINDMAZE THERAPEUTICS HOLDING SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
MINDMAZE THERAPEUTICS HOLDING SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.40 | 1.20 | - |
| Quick Ratio | 1.28 | 1.10 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | CHF2.93 Million | CHF2.22 Million | - |
MINDMAZE THERAPEUTICS HOLDING SA - Advanced Valuation Insights
This section examines the relationship between MINDMAZE THERAPEUTICS HOLDING SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.85 |
| Latest Market Cap to Assets Ratio | 0.55 |
| Asset Growth Rate (YoY) | 55308.6% |
| Total Assets | CHF51.53 Million |
| Market Capitalization | $28.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values MINDMAZE THERAPEUTICS HOLDING SA's assets below their book value (0.55x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: MINDMAZE THERAPEUTICS HOLDING SA's assets grew by 55308.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for MINDMAZE THERAPEUTICS HOLDING SA (2024–2025)
The table below shows the annual total assets of MINDMAZE THERAPEUTICS HOLDING SA from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CHF51.53 Million ≈ $65.15 Million |
+55308.60% |
| 2024-12-31 | CHF93.00K ≈ $117.58K |
-- |
About MINDMAZE THERAPEUTICS HOLDING SA
MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outp… Read more